Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more

Velocity Has Supported Research for 12 Products That Have Received FDA Approval in 2024

Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. Livdelzi … Read more

Paul Evans Featured in Business North Carolina Article on AI in the State’s Clinical Research Industry

Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on … Read more

An interview with Dr. Robert Cupelo on Alzheimer’s Treatment and the Legacy of Lecanemab

It’s been just over a year since the monoclonal antibody Lecanemab received traditional approval from the FDA as a treatment for Alzheimer’s disease. This marked a turning point in the disease’s treatment, a drug that interrupted progression for the first time rather than simply addressing the symptoms.  It was this type of breakthrough that Robert … Read more

The Importance of Diversity in Clinical Trials with Dr. Jerome Adams

The Velocity team had the honor of hosting former U.S. Surgeon General and Chairman of the Board of TOTAL Diversity Clinical Trial Management, Jerome Adams, MD, MPH. He joined an internal call to discuss the importance of diversity in clinical research, highlighting the need for diverse patient populations in clinical trials to ensure new treatments … Read more

Velocity Continues Rapid Growth with Luminis Health Partnership and Expansion into Oncology

Paul Evans, Velocity President and CEO, was featured in a Triangle Business Journal article covering Velocity’s recent partnership announcement with Luminis Health. As Paul notes in the article, hospitals play a crucial role in clinical research due to their patient populations, particularly in specialized fields like oncology. Velocity will take over the operation of the hospital’s … Read more

Dr. Kowdley Makes Significant Contributions to Pivotal Research Program for Ipsen’s Iqirvo for Primary Biliary Cholangitis

Kris Kowdley, MD, contributed significantly to the clinical research program that led to accelerated FDA approval of Ipsen’s Iqirvo, a first-in-class treatment for primary biliary cholangitis (PBC), a rare liver disease. As a primary investigator for the Phase 3 ELATIVE trial, Dr. Kowdley’s site enrolled the first patient in the study, and he was the … Read more

Velocity Partners with Luminis Health, Moves into Oncology in the U.S.

Velocity Clinical Research, the leading multi-specialty clinical sites business, and Luminis Health, a nonprofit health system providing care for 1.8 million people, today announce their partnership to conduct clinical research within the health group’s organization, connecting more patients with community-based research programs. The partnership will involve Velocity taking over operation of the hospital’s existing clinical … Read more